HERTFORDSHIRE, England and
PITTSBURGH, March 13, 2017 /PRNewswire/ -- Mylan N.V.
(NASDAQ, TASE: MYL), today announced the U.S. launch of Exemestane
Tablets, 25 mg, a generic version of the reference listed drug,
Pfizer's Aromasin® Tablets. Mylan received final approval from the
U.S. Food and Drug Administration (FDA) for its Abbreviated New
Drug Application (ANDA) for this product, which is indicated in the
treatment of certain types of breast cancer in women after
menopause.
Mylan is the largest supplier of cancer medicines by volume in
the U.S., and the launch of Exemestane Tablets, 25 mg, adds to the
company's robust oncology franchise. Exemestane Tablets, 25 mg, had
U.S. sales of approximately $100
million for the 12 months ending Jan.
31, 2017, according to IMS Health.
Currently, Mylan has 240 ANDAs pending FDA approval representing
approximately $100.8 billion in
annual brand sales, according to IMS Health. Forty-five of these
pending ANDAs are potential first-to-file opportunities,
representing $39 billion in annual
brand sales, for the 12 months ending Dec.
31, 2016, according to IMS Health.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of approximately 7,500 marketed products around the
world, including antiretroviral therapies on which approximately
50% of people being treated for HIV/AIDS in the developing world
depend. We market our products in more than 165 countries and
territories. We are one of the world's largest producers of active
pharmaceutical ingredients. Every member of our more than
35,000-strong workforce is dedicated to creating better health for
a better world, one person at a time. Learn more at mylan.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-launches-generic-aromasin-tablets-300422695.html
SOURCE Mylan N.V.